In the context of therapeutic intervention, the available drugs approved by the Food and Drug Administration (FDA) for AD patients, namely NMDA receptor 2 modulator (e.g., memantine), and cholinesterase inhibitors (e.g., rivastigmine, donepezil, and galantamine) can help to improve only quality of life and increase life expectancy. Here, BCHE is linked to Alzheimer disease.